カテゴリ： GlobalData, イギリス, 企業調査

Horizon Discovery Group Plc (HZD)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Horizon Discovery Group Plc (HZD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7949
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：110
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers services such as CRISPR screening, combination screening, in vivo assay services and cell-based assays, among others. Horizon Discovery offers its products and services to genomic research organizations, pharmaceutical, biotechnology and diagnostic companies and academic research centers for the formulation of customized medicines. The company has operations in the UK and the US. Horizon Discovery is headquartered in Cambridge, the UK.

Horizon Discovery Group Plc (HZD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17
Venture Financing 18
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 18
Private Equity 20
ValueAct Capital Acquires Additional Stake in Horizon Discovery Group from Woodford Investment Management 20
Partnerships 21
Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 21
Horizon Discovery Enters Into Licensing Agreement With ATCC 22
Celyad Enters into Agreement with Horizon Discovery 23
Horizon Discovery Enters into Partnership 24
Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 25
Horizon Discovery Enters into Research Agreement with Solentim 26
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 27
Horizon Discovery Enters into Agreement with Ubiquigent 28
Horizon Discovery Forms Joint Venture with Centauri Therapeutics 29
Horizon Discovery Partners with Axol Bioscience 30
Horizon Discovery Enters into Agreement with Swift Biosciences 31
Horizon Discovery Enters into Research Agreement with Redx Pharma 32
Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 33
CareDx Enters into Co-Development Agreement with Horizon Discovery 34
Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 35
Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 36
Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 37
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 38
Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 39
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 40
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 41
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 42
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 43
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 44
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 45
Licensing Agreements 46
Cytovance Biologics Enters into Licensing Agreement with Horizon Discovery 46
Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 47
ATUM Enters into Licensing Agreement with Horizon Discovery 48
Horizon Discovery Enters into Licensing Agreement with ATUM 49
Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 50
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 51
Horizon Discovery Enters into Licensing Agreement with Servier Lab 52
LakePharma Enters into Licensing Agreement with Horizon Discovery 53
Abcam Enters into Licensing Agreement with Horizon Discovery 54
Horizon Discovery Extends Licensing Agreement with ERS Genomics 55
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 56
Horizon Discovery Group Enters into Licensing Agreement 58
Horizon Discovery Enters into Licensing Agreement with ProteoNic 59
Horizon Discovery Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 61
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 62
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 63
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 64
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 65
Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 66
Equity Offering 67
Horizon Discovery Raises USD104.6 million in Private Placement of Shares 67
Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 68
Horizon Discovery Completes IPO For US$66.7 Million 69
Acquisition 71
Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 71
Horizon Discovery Acquires Haplogen Genomics for USD15 Million 73
Horizon Discovery Acquires Sage Labs for USD48 Million 74
Horizon Discovery Group Plc – Key Competitors 75
Horizon Discovery Group Plc – Key Employees 76
Horizon Discovery Group Plc – Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Joint Venture 78
Recent Developments 79
Financial Announcements 79
Sep 17, 2018: HORIZON DISCOVERY GROUP announce interim results for the six months ended 30 June 2018 79
May 08, 2018: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2017 84
Sep 26, 2017: Horizon Discovery Group: Interim Results For The Six Months Ended 30 June 2017 85
May 30, 2017: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2016 91
Corporate Communications 92
May 17, 2018: Horizon Discovery: Board Change 92
May 08, 2018: Horizon Discovery appoints Terry Pizzie as Chief Executive Officer 93
Mar 02, 2018: Horizon Discovery Group: Board Change 94
Feb 20, 2018: Horizon Discovery Announces Leadership Changes 95
Legal and Regulatory 96
Jul 03, 2017: Horizon Discovery announces inclusion of its Reference Standards in successful FDA approval of an oncology companion diagnostic test with leading next generation sequencing company 96
Government and Public Interest 97
Jul 17, 2017: Sphere Fluidics and Partners Win Major InnovateUK Grant to Develop the World’s First Desktop Genome Editing System 97
May 22, 2017: Horizon Discovery Announces New Gene Editing Technology Platform for Research and Therapeutic Applications 98
Product News 99
Nov 14, 2017: Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation 99
Aug 01, 2017: Horizon Discovery announces release of high quality, well annotated CHO genome sequence to drive innovation in bioproduction 100
May 26, 2017: Horizon Discovery introduces four BRAF resistant melanoma PDX models 102
Mar 26, 2018: Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening 103
Other Significant Developments 104
Sep 14, 2018: Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca as part of its functional genomics discovery platform 104
Mar 21, 2018: Horizon Discovery’s Bioproduction cell line used as part of a successful drug (IND) filing 105
Sep 18, 2017: Horizon Discovery announces launch of Genome-Wide CRISPRi and CRISPRa Screening Services 106
May 09, 2017: Horizon Discovery Announces Update on its Immuno-Oncology Platform including Strong Uptake of Product and Service Offerings 107
Jan 24, 2017: Horizon Discovery Group: Trading Update 108
Jan 13, 2017: International Trade Minister Greg Hands visits fast-growing Cambridge life sciences company 109
Appendix 110
Methodology 110
About GlobalData 110
Contact Us 110
Disclaimer 110

List of Tables
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 18
ValueAct Capital Acquires Additional Stake in Horizon Discovery Group from Woodford Investment Management 20
Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 21
Horizon Discovery Enters Into Licensing Agreement With ATCC 22
Celyad Enters into Agreement with Horizon Discovery 23
Horizon Discovery Enters into Partnership 24
Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 25
Horizon Discovery Enters into Research Agreement with Solentim 26
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 27
Horizon Discovery Enters into Agreement with Ubiquigent 28
Horizon Discovery Forms Joint Venture with Centauri Therapeutics 29
Horizon Discovery Partners with Axol Bioscience 30
Horizon Discovery Enters into Agreement with Swift Biosciences 31
Horizon Discovery Enters into Research Agreement with Redx Pharma 32
Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 33
CareDx Enters into Co-Development Agreement with Horizon Discovery 34
Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 35
Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 36
Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 37
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 38
Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 39
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 40
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 41
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 42
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 43
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 44
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 45
Cytovance Biologics Enters into Licensing Agreement with Horizon Discovery 46
Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 47
ATUM Enters into Licensing Agreement with Horizon Discovery 48
Horizon Discovery Enters into Licensing Agreement with ATUM 49
Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 50
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 51
Horizon Discovery Enters into Licensing Agreement with Servier Lab 52
LakePharma Enters into Licensing Agreement with Horizon Discovery 53
Abcam Enters into Licensing Agreement with Horizon Discovery 54
Horizon Discovery Extends Licensing Agreement with ERS Genomics 55
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 56
Horizon Discovery Group Enters into Licensing Agreement 58
Horizon Discovery Enters into Licensing Agreement with ProteoNic 59
Horizon Discovery Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 61
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 62
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 63
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 64
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 65
Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 66
Horizon Discovery Raises USD104.6 million in Private Placement of Shares 67
Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 68
Horizon Discovery Completes IPO For US$66.7 Million 69
Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 71
Horizon Discovery Acquires Haplogen Genomics for USD15 Million 73
Horizon Discovery Acquires Sage Labs for USD48 Million 74
Horizon Discovery Group Plc, Key Competitors 75
Horizon Discovery Group Plc, Key Employees 76
Horizon Discovery Group Plc, Other Locations 77
Horizon Discovery Group Plc, Subsidiaries 77
Horizon Discovery Group Plc, Joint Venture 78

List of Figures
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Horizon Discovery Group Plc (HZD)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • IBERIABANK Corporation：企業のM&A・事業提携・投資動向
    IBERIABANK Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IBERIABANK Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • SciDev Ltd：企業の戦略・SWOT・財務分析
    SciDev Ltd - Strategy, SWOT and Corporate Finance Report Summary SciDev Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Taiyo Nippon Sanso Corp. (4091)：企業の財務・戦略的SWOT分析
    Taiyo Nippon Sanso Corp. (4091) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Yapi ve Kredi Bankasi A.S.：戦略・SWOT・企業財務分析
    Yapi ve Kredi Bankasi A.S. - Strategy, SWOT and Corporate Finance Report Summary Yapi ve Kredi Bankasi A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • InterOil Corporation (IOC)-石油・ガス分野：企業M&A・提携分析
    Summary InterOil Corporation (InterOil) is an independent oil and gas company that carries out acquisition, exploration and development of oil and gas assets. It principally focuses on liquefied natural gas (LNG) projects in Papua New Guinea (PNG). It has several exploration licenses in the prospect …
  • Mapletree Investments Pte Ltd：企業の戦略的SWOT分析
    Mapletree Investments Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Johns Hopkins University：医療機器：M&Aディール及び事業提携情報
    Summary Johns Hopkins University (JHU) is a research university which offers undergraduate, graduate, master’s, and doctoral programs. It offers educational services in the areas of arts and sciences, engineering, business, medicine, nursing, public health, and advanced international studies. It als …
  • University of Pennsylvania-製薬・医療分野：企業M&A・提携分析
    Summary University of Pennsylvania (UOP) is an educational university that provides distance learning facilities for professional courses. The university offers courses such as art and archaeology, accounting, biochemistry, bioengineering, biomedical graduate studies, city and regional planning, cri …
  • Bezeq The Israel Telecommunication Corp. Ltd. (BEZQ)：企業の財務・戦略的SWOT分析
    Bezeq The Israel Telecommunication Corp. Ltd. (BEZQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Claret Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Claret Medical Inc (Claret Medical), a subsidiary of Boston Scientific Corp develops and commercializes cerebral protection systems. The company offers medical devices for cerebral protection during structural heart and vascular interventions, and cardiac surgery procedures. Its lead product …
  • Mendor Oy-医療機器分野：企業M&A・提携分析
    Summary Mendor Oy (Mendor) is a medical equipment company that designs, develops and markets advanced diabetes management products. The company’s products include portable blood glucose meter and web-based software application for the daily management of diabetes. It offers blood glucose meter mendo …
  • Tenaga Nasional Bhd (TENAGA)：企業の財務・戦略的SWOT分析
    Tenaga Nasional Bhd (TENAGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Reata Pharmaceuticals Inc (RETA)：企業の財務・戦略的SWOT分析
    Summary Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription fa …
  • Align Technology, Inc. (ALGN)-医療機器分野：企業M&A・提携分析
    Summary Align Technology, Inc. (Align) is a medical device company that designs, manufactures and markets orthodontics and services for orthodontic and restorative dentistry. The company’s portfolio encompasses a system of clear aligner therapy, intra-oral scanners, and computer-aided design, and co …
  • Keppel Land Limited：企業の戦略・SWOT・財務情報
    Keppel Land Limited - Strategy, SWOT and Corporate Finance Report Summary Keppel Land Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Carna Biosciences Inc (4572)：製薬・医療：M&Aディール及び事業提携情報
    Summary Carna Biosciences Inc (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive- …
  • KemPharm Inc (KMPH)：企業の財務・戦略的SWOT分析
    Summary KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the …
  • Arch Capital Group Ltd.：企業の戦略・SWOT・財務情報
    Arch Capital Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Arch Capital Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Vermillion Inc (VRML)：企業の財務・戦略的SWOT分析
    Summary Vermillion Inc (Vermillion) is a medical device company that discovers, develops and markets diagnostic and bio-analytical solutions that supports physicians to diagnose, treat and improve gynecologic health outcomes for women. The company’s in vitro diagnostic test OVA1, a simple blood test …
  • AdvantEdge Healthcare Solutions Inc-医療機器分野：企業M&A・提携分析
    Summary AdvantEdge Healthcare Solutions Inc (AdvantEdge) is a healthcare service provider that offers medical billing, coding and revenue cycle management solutions. The center’s solutions include medical billing, coding, reporting, dashboards and business intelligence, consulting and practice manag …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆